• To investigate whether a Continuous Glucose Monitoring System (CGMS) can improve metabolic control in pediatric subjects with type 1 diabetes.
• The endpoints for the study were HbA1c reduction and the duration and the frequency of hypoglycemia and hyperglycemia.
Methods
• A total of 32 subjects enrolled in the 24-week, controlled crossover study; study subjects were 12.5 ± 3.3 years of age (range: 5-19 years) and had an average duration of type 1 diabetes for 7.0 ± 3.9 years (range: 2-15 years).
• Subjects had an HbA1c of ≥6.8% at the beginning of the study.
• All subjects were treated with intensive insulin therapy; 14 subjects were treated with multiple daily injections (MDI) and 13 subjects were treated with insulin infusion pumps.
• The subjects were randomly placed into either an open or a blind study arm; both arms had subjects who used MDI therapy and pump therapy.
• Subjects in both arms wore the CGMS for 3 days every 2 weeks and were instructed to complete at least 2 self-monitoring blood glucose (SMBG) measurements and a 7-point SMBG once every week.
• The CGMS monitored interstitial glucose levels in subcutaneous tissue every 10 seconds and recorded an average value every 5 minutes.
• In the open arm, CGMS profi les were used to adjust insulin therapy at follow-up visits every 6 weeks.
• In the blinded arm, both the subjects and the diabetes team were masked to the CGMS profi les. Insulin therapy adjustments were based solely on 7-point blood glucose profi les performed by the subjects.
• After 3 months, the open and blinded study arms crossed over.
Results

HbA1c
• Twenty-seven subjects completed the study; the mean baseline HbA1c value was 8.0% ± 1.1% (range 6.8% -10.8%).
• During the fi rst 3-month period, there was a decrease in HbA1c levels in both the open and blinded study arms.
• After the 3-month crossover, the now open study arm had a further decrease in HbA1c levels, and the now blinded arm had an increase in HbA1c levels.
• During the open arm, subjects had a mean HbA1c reduction from 7.70% to 7.31% (p=0.013), which was signifi cant. In comparison, the blinded arm had a mean HbA1c reduction from 7.75% to 7.65% (p=NS).
Hyperglycemia
• On average, there were 1.5 episodes per day of daytime high subcutaneous glucose (>270 mg/dL or >15 mmol/L; duration 126 ± 33 minutes, 19.4% of total time) and there were 0.6 episodes per night (duration 177 ± 83 minutes, 25.5% of total time).
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Hypoglycemia
• Twenty-six of 27 subjects experienced daytime low glucose values. These subjects, on average, experienced 0.8 episodes per day (<54 mg/dL or <3.0 mmol/L, duration 58 ± 29 minutes, 5.5% of total time) and all subjects had at least 1 night-time episode of low glucose.
• There was no diff erence in hypoglycemia frequency between the open and blinded arms, nor between the MDI and infusion pump subjects.
• Two subjects experienced severe hypoglycemia during the study; 1 occurred during the blinded arm and one occurred during the open arm.
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(Hypoglycemia is defi ned as <3.0 mmol/L or <54 mg/dL; Hyperglycemia is defi ned as >15mmol/L or >273 mg/dL) 
Conclusions
• Adjustments to insulin therapy based on CGMS profi les improved metabolic control in pediatric subjects with type 1 diabetes.
• Subjects in the open arm reduced their HbA1c levels signifi cantly without increasing their frequency of hypoglycemia.
• Improvements in HbA1c levels for subjects initially randomized to the blinded arm may be attributed to a study eff ect related to more frequent clinic visits and enthusiasm to see CGMS profi les in the future open arm.
• The use of CGMS may benefi t patients with elevated HbA1c levels, a worrying increase of HbA1c levels, known or suspected hypoglycemia, a lack of motivation and/or understanding of blood glucose self-monitoring, and those who want to learn more about the eff ect of meals and/or physical exercise on their blood glucose.
